Mencevax™ACWY

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline

Conditions

Infections, Meningococcal

Phase 2

Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old

CompletedNCT00196976

GlaxoSmithKlineInfections, Meningococcal

Start: 2005-03-24End: 2006-03-03Updated: 2018-06-08

Phase 3

Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults

CompletedNCT00453986

GlaxoSmithKlineInfections, Meningococcal

Start: 2007-04-09End: 2008-05-21Updated: 2018-09-25

Related Papers

The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: a randomized, controlled non-inferiority study.

2012-04-0923 citations

The investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults.

2012-04-0916 citations